RxDoctor Payments Data

Nicholas Debolt, PA

Surgical · Tulsa, OKNPI 1700122587

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Smith+Nephew accounts for 61.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $422 and has fallen 77.3% since, to $96 in 2025.

$775in general payments, 2019–2025

Across 26 payments — averaging $29.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$473
  • Pacira Therapeutics, Inc.$74
  • Vertex$60
  • Pylant Medical$47
  • Ferring Pharmaceuticals Inc.$36
  • Stryker$27
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$775100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$775 in reported general payments places this provider in the 60th percentile of 94 surgical providers in Oklahoma.

See all surgical providers in Oklahoma

Medicare billing

Part B allowed, 2024
$99,728
Medicare patients
243
Services billed
2,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam24$199
Methylprednisolone19$135

Paid to pharmacies, not to this prescriber.

Other surgical in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →